Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies

被引：0
|
作者：
Vermersch, P. [1 ]
Comi, G. [2 ]
Siva, A. [3 ]
Oreja-Guevara, C. [4 ]
Wiendl, H. [5 ]
Van Wijmeersch, B. [6 ]
Eralinna, J. -P. [7 ]
Nicholas, R. [8 ]
Buffels, R. [9 ]
Bernasconi, C. [9 ]
Kuhelj, R. [9 ]
机构：
[1] Univ Lille, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Istanbul Univ, Istanbul, Turkey
[4] Univ Hosp San Carlos, Madrid, Spain
[5] Univ Munster, Munster, Germany
[6] Univ Hasselt, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium
[7] Univ Turku, Turku, Finland
[8] Imperial Coll London, London, England
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2077
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [41] Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis
    Lucchetta, Rosa C.
    Leonart, Leticia P.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 7 - 15
  • [42] Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Martinez-Lopez, Iciar
    Maurino, Jorge
    Sanmartin-Fenollera, Patricia
    Ontanon-Nasarre, Ana
    Santiago-Perez, Alejandro
    Moya-Carmona, Isabel
    Gustavo Garcia-Collado, Carlos
    Fernandez-Del Olmo, Raquel
    Garcia-Arcelay, Elena
    Sarmiento, Monica
    Carreno, Agata
    Perez-Encinas, Montserrat
    PHARMACY, 2020, 8 (02)
  • [43] Using number needed to treat to compare the efficacies of disease-modifying therapies in relapsing-remitting multiple sclerosis
    Mikol, D.
    Bennett, R.
    Divan, V.
    Hughes, B.
    AL-Sabbagh, A.
    JOURNAL OF NEUROLOGY, 2007, 254 : 136 - 136
  • [44] New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
    Nicholas, J.
    Morgan-Followell, B.
    Pitt, D.
    Racke, M. K.
    Boster, A.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2012, 4 : 81 - 103
  • [45] Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
    Rudick, RA
    ARCHIVES OF NEUROLOGY, 1999, 56 (09) : 1079 - 1084
  • [46] Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis
    Rollot, F.
    Casey, R.
    Debouverie, M.
    Edan, G.
    Wiertlewski, S.
    Leray, E.
    Vukusic, S.
    Laplaud, D-A
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 344 - 345
  • [47] Year one interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior diseasemodifying treatments
    Leist, T. P.
    Reder, A. T.
    Bermel, R.
    Weinstock-Guttman, B.
    Freedman, M. S.
    Cutter, G.
    Stankiewicz, J.
    Zheng, H.
    Musch, B.
    Csoboth, C.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 318 - 319
  • [48] Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison
    Freedman, Mark S.
    Hughes, Bruce
    Mikol, Daniel D.
    Bennett, Randy
    Cuffel, Brian
    Divan, Vamil
    LaVallee, Nicole
    Al-Sabbagh, Ahmad
    EUROPEAN NEUROLOGY, 2008, 60 (01) : 1 - 11
  • [49] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
    Roos, I.
    Malpas, C.
    Leray, E.
    Casey, R.
    Horakova, D.
    Havrdova, E. Kubala
    Debouverie, M.
    Patti, F.
    De Seze, J.
    Izquierdo, G.
    Eichau, S.
    Edan, G.
    Prat, A.
    Girard, M.
    Ozakbas, S.
    Grammond, P.
    Zephir, H.
    Ciron, J.
    Maillart, E.
    Moreau, T.
    Amato, M. P.
    Labauge, P.
    Alroughani, R.
    Buzzard, K.
    Skibina, O.
    Terzi, M.
    Laplaud, D.
    Berger, E.
    Grand'Maison, F.
    Lebrun-Frenay, C.
    Cartechini, E.
    Boz, C.
    Lechner-Scott, J.
    Clavelou, P.
    Stankoff, B.
    Prevost, J.
    Kappos, L.
    Pelletier, J.
    Shaygannejad, V.
    Yamout, B.
    Gerlach, O.
    Spitaleri, D.
    van Pesch, V.
    Gout, O.
    Turkoglu, R.
    Heinzlef, O.
    Thouvenot, E.
    Vukusic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 673 - 676
  • [50] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
    Roos, I.
    Malpas, C. B.
    Leray, E.
    Buzzard, K.
    Skibina, O.
    Lechner-Scott, J.
    McCombe, P.
    Slee, M.
    Butler, E.
    Macdonell, R.
    van der Walt, A.
    Hodgkinson, S.
    Barnett, M.
    Vucic, S.
    Vukusic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 6 - 7
12345